A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4614 participants.

Also called NCT02415400

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose other
Phase
Phase 4
Enrolled
  • 4,614 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02415400
  • EudraCT 2014-002004-24
Other papers using this trial's data
  • Antithrombotic Strategies According to Age: Insights from the AUGUSTUS Trial The American journal of medicine, 2024-10 DOI, PubMed 38876331
  • Antithrombotic Strategies in Atrial Fibrillation After ACS and/or PCI: A 4-Way Comparison From AUGUSTUS Journal of the American College of Cardiology, 2024-09-03 DOI, PubMed 39197976
  • Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation The New England journal of medicine, 2019-04-18 DOI, PubMed 30883055
  • Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention Journal of the American College of Cardiology, 2022-02-08 DOI, PubMed 35115097
  • Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial Circulation, 2019-12-03 DOI, PubMed 31557056
  • Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS Journal of the American College of Cardiology, 2025-03-25 DOI, PubMed 39918467
  • Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial JAMA cardiology, 2022-07-01 DOI, PubMed 35612866, PMC9134037 Not in the PMC Open Access subset.
  • Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS American heart journal, 2025-02 DOI, PubMed 39557109
  • Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial Open heart, 2022-02 DOI, PubMed 35172988, PMC8852719 In the PMC Open Access subset under CC BY-NC.
  • Relative Benefit of Dual Versus Single Antiplatelet Therapy Among Patients With Atrial Fibrillation on Oral Anticoagulation According to Time After ACS and PCI: Insights From the AUGUSTUS Trial Circulation. Cardiovascular interventions, 2024-11 DOI, PubMed 39502066

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia, Denmark, France, Germany, Hungary, India, Israel, Italy, Mexico, Netherlands, Norway, Peru, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Slovakia, South Korea, Spain, Sweden, Switzerland, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02415400. Randomized; no masking; primary purpose other. Start 2015-06-04 (actual); primary completion 2018-11-10 (actual). Results posted on 2020-02-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart
Condition
Acute Coronary Syndromes
Intervention (Drug)
Apixaban
Intervention (Drug)
vitamin K antagonist
Intervention (Drug)
Acetylsalicylic acid
Intervention (Other)
Acetylsalicylic acid placebo
Lead sponsor
Bristol-Myers Squibb (class: industry)
Collaborator
Pfizer (class: industry)
Collaborator
Duke Clinical Research Institute (class: other)

Record details

Record id
cardio:ct-nct02415400
Content hash
9562f7c4475d9cf002c6d1bfbc5ed8ca33826ee901046f646fcbae2cd25e7128